"Sodium Channel Blockers" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs that act by inhibition of sodium influx through cell membranes. Blockade of sodium channels slows the rate and amplitude of initial rapid depolarization, reduces cell excitability, and reduces conduction velocity.
| Descriptor ID |
D026941
|
| MeSH Number(s) |
D27.505.519.562.750 D27.505.954.411.720
|
| Concept/Terms |
Sodium Channel Blockers- Sodium Channel Blockers
- Sodium Channel Inhibitors
- Channel Inhibitors, Sodium
- Inhibitors, Sodium Channel
- Channel Blockers, Sodium
|
Below are MeSH descriptors whose meaning is more general than "Sodium Channel Blockers".
Below are MeSH descriptors whose meaning is more specific than "Sodium Channel Blockers".
This graph shows the total number of publications written about "Sodium Channel Blockers" by people in this website by year, and whether "Sodium Channel Blockers" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 2 | 1 | 3 |
| 1998 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 2 | 0 | 2 |
| 2002 | 0 | 2 | 2 |
| 2003 | 2 | 0 | 2 |
| 2004 | 2 | 0 | 2 |
| 2005 | 1 | 1 | 2 |
| 2006 | 1 | 2 | 3 |
| 2007 | 1 | 1 | 2 |
| 2008 | 3 | 1 | 4 |
| 2009 | 3 | 1 | 4 |
| 2010 | 2 | 3 | 5 |
| 2011 | 5 | 1 | 6 |
| 2012 | 1 | 2 | 3 |
| 2013 | 3 | 1 | 4 |
| 2014 | 1 | 2 | 3 |
| 2015 | 2 | 1 | 3 |
| 2016 | 4 | 3 | 7 |
| 2017 | 1 | 1 | 2 |
| 2018 | 1 | 1 | 2 |
| 2019 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Sodium Channel Blockers" by people in Profiles.
-
Burashnikov A. Depolarization of the atrial resting membrane potential as an approach to enhance the anti-atrial fibrillation efficacy of sodium channel blockers. Heart Rhythm. 2021 07; 18(7):1221-1222.
-
Burashnikov A. Investigational Anti-Atrial Fibrillation Pharmacology and Mechanisms by Which Antiarrhythmics Terminate the Arrhythmia: Where Are We in 2020? J Cardiovasc Pharmacol. 2020 11; 76(5):492-505.
-
Burashnikov A, Barajas-Martinez H, Hu D, Robinson VM, Grunnet M, Antzelevitch C. The Small Conductance Calcium-Activated Potassium Channel Inhibitors NS8593 and UCL1684 Prevent the Development of Atrial Fibrillation Through Atrial-Selective Inhibition of Sodium Channel Activity. J Cardiovasc Pharmacol. 2020 08; 76(2):164-172.
-
Stabenau HF, Shen C, Tereshchenko LG, Waks JW. Changes in global electrical heterogeneity associated with dofetilide, quinidine, ranolazine, and verapamil. Heart Rhythm. 2020 03; 17(3):460-467.
-
Sicouri S, Belardinelli L, Antzelevitch C. Effect of autonomic influences to induce triggered activity in muscular sleeves extending into the coronary sinus of the canine heart and its suppression by ranolazine. J Cardiovasc Electrophysiol. 2019 02; 30(2):230-238.
-
Argenziano M, Antzelevitch C. Recent advances in the treatment of Brugada syndrome. Expert Rev Cardiovasc Ther. 2018 Jun; 16(6):387-404.
-
Burashnikov A. Late INa Inhibition as an Antiarrhythmic Strategy. J Cardiovasc Pharmacol. 2017 Sep; 70(3):159-167.
-
Burashnikov A, Antzelevitch C. Effectiveness of Late INa Versus Peak INa Block in the Setting of Ventricular Fibrillation. Circ Arrhythm Electrophysiol. 2017 03; 10(3).
-
Chorin E, Hu D, Antzelevitch C, Hochstadt A, Belardinelli L, Zeltser D, Barajas-Martinez H, Rozovski U, Rosso R, Adler A, Benhorin J, Viskin S. Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data. Circ Arrhythm Electrophysiol. 2016 Oct; 9(10).
-
Asadi-Pooya AA. Phenytoin for neuroprotection. Lancet Neurol. 2016 08; 15(9):901.